ImmuCell to Report Quarterly Results November 12
ImmuCell Corporation will release unaudited financial results for the quarter ended September 30, 2026, after market close.
Updated on Nov. 6, 2026 in Public Companies
ImmuCell Corporation, an animal health biologics company listed on Nasdaq under ICCC, will report unaudited financial results for the quarter ended September 30, 2026. The company will file its Quarterly Report on Form 10-Q on November 12, 2026, after the market closes, and anticipates no change to preliminary sales results disclosed October 12, 2026.
Why it matters
The filing will give investors and stakeholders the full quarterly financial picture for the company's calf health products, including its First Defense line. Results are expected to be presented alongside a conference call for further detail.
Preliminary sales for the quarter ended September 30, 2026 were disclosed October 12, 2026, and ImmuCell anticipates no change to them. The complete unaudited results and Form 10-Q will be released November 12, 2026, after market close.
The players
ImmuCell Corporation
An animal health biologics company listed on Nasdaq under ICCC that develops products to improve calf health and productivity.
The details
ImmuCell Corporation develops, manufactures and markets products to improve calf health and productivity. Its First Defense product line delivers colostrum-derived antibodies orally to provide immunity against the principal viral and bacterial causes of scours, a leading cause of neonatal calf illness and death.
Timeline
October 12, 2026: Preliminary sales results for the quarter were disclosed.
September 30, 2026: The quarter under report ended.
November 12, 2026: Unaudited results and Form 10-Q are expected after market close.
November 13, 2026: Conference call and webcast begin at 9:00 AM ET.
November 20, 2026: Teleconference replay of the call expires.
Market Landscape
The quarterly report offers a measure of how ImmuCell's First Defense colostrum-based oral antibody products are performing in the animal health market. Investors will compare the reported results against the company's preliminary sales figures released in October.
Shareholders and prospective investors can review the complete quarterly numbers and management commentary once results are released November 12. Those following ImmuCell can join the November 13 call or replay it through November 20.
The takeaway
Investors tracking small-cap animal health companies should watch the November 12 results for confirmation of the preliminary sales trend. The conference call on November 13 may offer management's view on the quarter's performance.
What happens next
ImmuCell will host a conference call and webcast on November 13, 2026 at 9:00 AM ET to review the unaudited quarterly results.
Further reading
For more on how publicly traded firms report their results, explore Public Companies coverage.
More information
Visit the ImmuCell investor relations page for presentation slides and additional company filings.
Source note: This article includes information reported by The Manila times.
